Table 1.
Ongoing or completed clinical trials with OVs encoding immunostimulatory transgenes
| Virus | Name (Institution) | Transgenes | Tumor type | Reference/identifier | Phase/status |
|---|---|---|---|---|---|
| CG0070 (CG Oncology) | GM-CSF | Bladder cancer | NCT02365818 | Phase II Completed | |
| Nonmuscular invasive bladder cancer | NCT04452591 | Phase III Recruiting | |||
| TILT-123 (TILT Biotherapeutics) | TNF-α and IL-2 | Solid tumor | NCT04695327 | Phase I Recruiting | |
| Metastatic melanoma | NCT04217473 | Phase I Recruiting | |||
| Adenovirus | NG-641 (PsiOxus Therapeutics) | Anti-FAP-TAc antibody CXCL9/CXCL10/IFNα |
Metastatic cancer Epithelial tumor |
NCT04053283 | Phase I Recruiting |
| ONCOS-102 (Targovax) | GM-CSF | Malignant solid tumor | NCT01598129 | Phase I Completed | |
| NG-350A (PsiOxus Therapeutics) | Anti-CD40 antibody |
Metastatic cancer Epithelial tumor |
NCT03852511 | Phase I Recruiting | |
| DNX-2440 (DNAtrix) | OX40 ligand |
Liver metastases Liver metastasis of Colon cancer Colorectal cancer Breast cancer Gastric cancer Periampullary cancer Melanoma Renal cell cancer Sarcoma Squamous cell carcinoma Gastrointestinal stromal tumors |
NCT04714983 | Phase I Recruiting | |
| Glioblastoma | NCT03714334 | Phase I Recruiting | |||
| OH2 (Wuhan Binhui Biotechnology) | GM-CSF |
Solid tumor Gastrointestinal cancer |
NCT03866525 | Phase I/II Recruiting | |
| Pancreatic cancer | NCT04637698 | Phase I/II Recruiting | |||
| Talimogene laherparepvec (Amgen) | GM-CSF | Peritoneal surface malignancies | NCT03663712 | Phase I Recruiting | |
| Kaposi sarcoma | NCT04065152 | Phase II Recruiting | |||
| Melanoma | NCT04427306 | Phase II Recruiting | |||
| HSV | VG161 (CNBG-Virogin Biotech) | IL12/15/PDL1B | Advanced malignant solid tumor | NCT04758897 | Phase I Recruiting |
| Primary liver cancer | NCT04806464 | Phase I Recruiting | |||
| M032 (University of Alabama at Birmingham) | IL12 |
Recurrent glioblastoma Multiforme progressive glioblastoma Multiforme anaplastic astrocytoma or gliosarcoma |
NCT02062827 | Phase I Recruiting | |
| VV | JX-594 (Jennerex Biotherapeutics Green Cross Corporation) | GM-CSF | Liver cancer | NCT00629759 | Phase I Completed |
|
Melanoma Lung cancer Renal cell carcinoma Squamous cell Carcinoma of the head and neck |
NCT00625456 | Phase I Completed | |||
|
Hepatocellular carcinoma liver cancer (HCC) |
NCT01387555 | Phase II Completed | |||
|
Neuroblastoma Rhabdomyosarcoma Lymphoma Wilm’s tumor Ewing’s sarcoma |
NCT01169584 | Phase I Completed | |||
| Melanoma | NCT00429312 | Phase I/II Completed | |||
| ASP9801 (Astellas Pharma) | IL-7 IL-12 |
Metastatic cancer Solid tumors Advanced cancer |
NCT03954067 | Phase I Recruiting | |
| RGV004 (Second Affiliated Hospital, School of Medicine, Zhejiang University) | Anti-CD19/anti-CD3 bispecific antibody | Relapsed or refractory B-cell lymphoma | NCT04887025 | Phase I Not, yet recruiting | |
| VSV | Given IV (Mayo Clinic) | IFN-β NIS |
Relapsed or refractory multiple myeloma Acute myeloid leukemia T-cell lymphoma |
NCT03017820 | Phase I Recruiting |